Drug Profile
Pegfilgrastim biosimilar - Shandong New Time Pharmaceutical
Latest Information Update: 25 Nov 2021
Price :
$50
*
At a glance
- Originator Shandong New Time Pharmaceutical Co LTD
- Class Antineoplastics; Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Leucopenia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Leucopenia(In volunteers) in China (Injection)